Dermata terminates Villani license, pivots to OTC skin care

Dermata Therapeutics, Inc.

Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.
Eliminates future milestone payments of up to $40.5M and single-digit royalties.
Strategic shift: will commercialize OTC skin care; withdrew XYNGARI IND.
License covered exclusive rights to sponge-based products for skin disease treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.